Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ? 50%: Results from EMPOWER-Lung 1 study. için istatistikler
Toplam ziyaret
| views | |
|---|---|
| Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ? 50%: Results from EMPOWER-Lung 1 study. | 0 |
Aylık toplam ziyaret
| views | |
|---|---|
| Mayıs 2024 | 0 |
| Haziran 2024 | 0 |
| Temmuz 2024 | 0 |
| Ağustos 2024 | 0 |
| Eylül 2024 | 0 |
| Ekim 2024 | 0 |
| Kasım 2024 | 0 |
